SCHEMBL30259285

SCHEMBL30259285

Ic1cncnc1OCC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.38
CDK1 P06493 2/20 0.38
ACACB O00763 2/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR7 P34969 2/20 0.32
HTR4 Q13639 2/20 0.32
DHFR P00374 1/20 0.32
FFAR2 O15552 1/20 0.32
HTR2B P41595 1/20 0.32
HTR3A P46098 1/20 0.32
HTR5A P47898 1/20 0.32
EP300 Q09472 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
CNR2 P34972 1/20 0.31
CCNB1 P14635 1/20 0.31
CCNA2 P20248 1/20 0.31
CCNA1 P78396 1/20 0.31
HTR1A P08908 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10273189 0.73 CYP17A1 (0.39)
SCHEMBL22834444 0.72 DHFR (0.46) CDK2CDK1DHFRCCNB1CCNA2
SCHEMBL30819614 0.72 CHUK (0.38) CDK2CDK1CNR2CCNB1CCNA2
SCHEMBL760442 0.71 HTR2C (0.45) CDK2CDK1HTR2AHTR2CHTR7
SCHEMBL28137688 0.71 CDK2 (0.48) CDK2CDK1FFAR2CNR2CCNB1
SCHEMBL12635217 0.70 APP (0.48)
SCHEMBL10188533 0.69 GSK3A (0.39) GSK3AGSK3B
SCHEMBL17861726 0.69 EP300 (0.43) CDK2CDK1HTR4HTR3AEP300
SCHEMBL22111082 0.69 ACACB (0.37) CDK2CDK1ACACB
SCHEMBL20732647 0.68 ACACB (0.39) CDK2CDK1ACACBFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 CDK2 446/4885CDK1 412/4885ACACB 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.